Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
Costs of robot-assisted surgery: While it is unlikely that robot-assisted surgery with devices like Intuitive Surgical's da Vinci system will completely replace conventional surgery, such a substitution would generate $1.5 billion in additional health care costs annually, Gabriel Barbash, Sackler School of Medicine, Tel Aviv University, and Sherry Glied, Mailman School of Public Health, Columbia University, write in the New England Journal of Medicine Aug. 18. Including the amortized costs of the robots, the total would be $2.5 billion. Per procedure (including the amortized cost of the device), the robots add about $3,200. The authors note that the number of robot-assisted procedures performed worldwide has tripled since 2007, and from 2007 to 2009, the number of da Vinci systems installed in the U.S. grew from 800 to 1,400. Barbash and Glied assert that evidence from well designed, large-scale trials or another equally rigorous evaluation is needed to determine which types of patients benefit from open surgical approaches and which from robot-assisted approaches
You may also be interested in...
Laparoscopic Hysterectomy Is Cheaper Than Robotic Version With Similar Results
Large study questions the cost-effectiveness of robotic hysterectomy for benign gynecologic condition.
ASCO Meeting In Brief
Brain cancer device makes headway: Israel-based NovoCure plans a near-term PMA submission for its NovoTTF brain cancer device, a portable headgear-based system that relies on low intensity electric fields to disrupt cell division, based on data from a 237-subject trial of recurrent glioblastoma patients reported June 5 at the American Society of Clinical Oncology annual meeting. In the full "intent-to-treat" population, the NovoTTF arm showed statistically similar survival times to "best available" chemotherapies (6.6 months vs. 6.0 months), researchers reported at the Chicago meeting. In the "per-protocol" population - the 80% of patients that completed at least one course of device or drug treatment - NovoTTF patients experienced a statistically significant survival advantage (7.8 months vs. 6.1 months) and a large advantage in response rate (15.1% vs. 5.1%). The CE-marked device, which a patient can wear throughout the day while toting a battery pack in an over-the-shoulder bag, was associated with three to four times fewer infections than standard chemotherapy, plus a reduction in other common side effects. NovoCure is conducting another pivotal trial assessing the impact of combining the device with chemotherapy for newly diagnosed glioblastomas. The firm recently raised funds from Pfizer, Johnson & Johnson and other investors to help fund its clinical trial program (1"The Gray Sheet" Oct. 12, 2009)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”